FDA Warning Letter — Namita A. Goyal, M.D.

Case 677324 — FEI 3018752619

The FDA took a Warning Letter action against Namita A. Goyal, M.D. on October 10, 2024 (Orange, CA). The action was issued by CBER and concerns biologics products. This facility has 1 recent FDA inspection on record.

Action Details

Facility
Namita A. Goyal, M.D.
Date
October 10, 2024
Fiscal Year
2025
Product Type
Biologics
Center
CBER
Location
Orange, CA (United States)